Asthenozoospermia was seen in 43% patients (n = 516), either singly, or in combination with other semen disorders. For this study, 186 patients were divided into two groups of 93 patients each. In the treated group, the patients were advised vitamin A and E therapy for 12 weeks, while the placebo group was not administered anything. In all the patients in the treated group, sperm motility increased significantly (p < 0.05). The mean motility increase in the treated group was from 28.28+0.79 to 54.96+1.14, while in the placebo group it increased from 28.69+0.73 to 29.37+0.73. Similarly, another semen quality limiting factor is sperm agglutination, which is an immunologic problem. Patients demonstrating sperm agglutination (n = 207) were advised Vitamin C therapy for three months and it was seen that sperm agglutination was removed n 88.4% of these patients. The placebo group for these patients comprised 211 subjects, who were not administered anything. The agglutination persisted in 194 subjects representing the placebo group when they were re-examined after a period of three months.
08 - 11 Apr 2002
British Endocrine Societies